Clinical Trials Logo

Clinical Trial Summary

NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression with suicidal ideation. This study will test the hypothesis that NRX-101 is superior to lurasidone alone (standard of care) in maintaining remission from symptoms of depression (primary endpoint) and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.


Clinical Trial Description

Background and Rationale: NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NRX-101 is composed of D-cycloserine (DCS) an NMDA antagonist and lurasidone (5HT2a atypical antipsychotic and antidepressant). In a phase 2 clinical study of bipolar depression and acute suicidal ideation and behavior, (in patients requiring hospitalization) patients received an initial infusion of ketamine and then NRX-101 for 6 weeks. In that phase 2 study, NRX-101 showed the ability to maintain remission from depression and suicidality over 6 weeks when taken twice daily. In this current out patient study, patients with bipolar depression and subacute suicidality (not requiring hospitalization), ketamine will not be used. Primary Objective: - To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization. Secondary Objectives: • To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in reducing suicidality in depressed bipolar patients with SSIB, as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) Methodology: : A multi-center, randomized, double-blind, trial in which patients with bipolar depression (MADRS ≥30) and subacute levels of suicidal ideation (C-SSRS 3 or 4, not requiring hospitalization) are randomized to receive twice daily oral NRX-101 or lurasidone (standard of care). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03395392
Study type Interventional
Source NeuroRx, Inc.
Contact
Status Completed
Phase Phase 2/Phase 3
Start date May 12, 2022
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Recruiting NCT03396744 - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression Phase 1/Phase 2
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Completed NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Terminated NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Recruiting NCT04998773 - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression N/A
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Completed NCT03658824 - Behavioural Activation for Bipolar Depression: A Case Series N/A
Suspended NCT03674671 - Ketamine Versus Electroconvulsive Therapy in Depression Phase 3
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Recruiting NCT05296356 - OSU6162 in Bipolar Depression (OBID) Phase 2
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1